D N Shah1, S L Aitken2, L F Barragan3, S Bozorgui3, S Goddu3, M E Navarro3, Y Xie4, H L DuPont5, K W Garey6. 1. Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA. 2. Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Internal Medicine Service, Baylor St Luke's Medical Center, Houston, TX, USA. 4. Department of Outcomes Research, Merck & Co., Whitehouse Station, NJ, USA. 5. Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA; Internal Medicine Service, Baylor St Luke's Medical Center, Houston, TX, USA; Division of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA; Center for Infectious Diseases, University of Texas School of Public Health, Houston, TX, USA. 6. Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA; Center for Infectious Diseases, University of Texas School of Public Health, Houston, TX, USA. Electronic address: kgarey@uh.edu.
Abstract
BACKGROUND: Few studies have investigated the additional healthcare costs of recurrent C. difficile infection (CDI). AIM: To quantify inpatient treatment costs for CDI and length of stay among hospitalized patients with primary CDI only, compared with CDI patients who experienced recurrent CDI. METHODS: This was a prospective, observational cohort study of hospitalized adult patients with primary CDI followed for three months to assess for recurrent CDI episodes. Total and CDI-attributable hospital length of stay (LOS) and hospitalization costs were compared among patients who did or did not experience at least one recurrent CDI episode. FINDINGS: In all, 540 hospitalized patients aged 62±17 years (42% males) with primary CDI were enrolled, of whom 95 patients (18%) experienced 101 recurrent CDI episodes. CDI-attributable median (interquartile range) LOS and costs (in US$) increased from 7 (4-13) days and $13,168 (7,525-24,456) for patients with primary CDI only versus 15 (8-25) days and $28,218 (15,050-47,030) for patients with recurrent CDI (P<0.0001, each). Total hospital median LOS and costs increased from 11 (6-22) days and $20,693 (11,287-41,386) for patients with primary CDI only versus 24 (11-48) days and $45,148 (20,693-82,772) for patients with recurrent CDI (P<0.0001, each). The median cost of pharmacological treatment while hospitalized was $60 (23-200) for patients with primary CDI only (N=445) and $140 (30-260) for patients with recurrent CDI (P=0.0013). CONCLUSION: This study demonstrated that patients with CDI experience a significant healthcare economic burden attributed to CDI. Economic costs and healthcare burden increased significantly for patients with recurrent CDI.
BACKGROUND: Few studies have investigated the additional healthcare costs of recurrent C. difficile infection (CDI). AIM: To quantify inpatient treatment costs for CDI and length of stay among hospitalized patients with primary CDI only, compared with CDIpatients who experienced recurrent CDI. METHODS: This was a prospective, observational cohort study of hospitalized adult patients with primary CDI followed for three months to assess for recurrent CDI episodes. Total and CDI-attributable hospital length of stay (LOS) and hospitalization costs were compared among patients who did or did not experience at least one recurrent CDI episode. FINDINGS: In all, 540 hospitalized patients aged 62±17 years (42% males) with primary CDI were enrolled, of whom 95 patients (18%) experienced 101 recurrent CDI episodes. CDI-attributable median (interquartile range) LOS and costs (in US$) increased from 7 (4-13) days and $13,168 (7,525-24,456) for patients with primary CDI only versus 15 (8-25) days and $28,218 (15,050-47,030) for patients with recurrent CDI (P<0.0001, each). Total hospital median LOS and costs increased from 11 (6-22) days and $20,693 (11,287-41,386) for patients with primary CDI only versus 24 (11-48) days and $45,148 (20,693-82,772) for patients with recurrent CDI (P<0.0001, each). The median cost of pharmacological treatment while hospitalized was $60 (23-200) for patients with primary CDI only (N=445) and $140 (30-260) for patients with recurrent CDI (P=0.0013). CONCLUSION: This study demonstrated that patients with CDI experience a significant healthcare economic burden attributed to CDI. Economic costs and healthcare burden increased significantly for patients with recurrent CDI.
Authors: Jennifer L Kuntz; Jennifer M Baker; Patricia Kipnis; Sherian Xu Li; Vincent Liu; Yang Xie; Stephen Marcella; Gabriel J Escobar Journal: Infect Control Hosp Epidemiol Date: 2016-10-20 Impact factor: 3.254
Authors: Masaad Saeed Almutairi; Anne J Gonzales-Luna; Faris S Alnezary; Saad B Fallatah; M Jahangir Alam; Khurshida Begum; Kevin W Garey Journal: Anaerobe Date: 2021-08-27 Impact factor: 3.331
Authors: Kelly R Reveles; Kierra M Dotson; Anne Gonzales-Luna; Dhara Surati; Bradley T Endres; M Jahangir Alam; Kevin W Garey Journal: Clin Infect Dis Date: 2019-05-17 Impact factor: 9.079
Authors: Bryan T Nycz; Samuel R Dominguez; Deborah Friedman; Joanne M Hilden; Diana Ir; Charles E Robertson; Daniel N Frank Journal: PLoS One Date: 2018-01-12 Impact factor: 3.240
Authors: Vimalanand S Prabhu; Oliver A Cornely; Yoav Golan; Erik R Dubberke; Sebastian M Heimann; Mary E Hanson; Jane Liao; Alison Pedley; Mary Beth Dorr; Stephen Marcella Journal: Clin Infect Dis Date: 2017-10-01 Impact factor: 9.079